LabCorp scoops up Monogram Biosciences for $106M

LabCorp has struck a deal to buy Monogram Biosciences for $106.7 million, a deal that will give the company a new set of tools used in drug discovery work. The acquisition today also highlights LabCorp's rapid expansion as it continues on a buyout spree.

A variety of developers, including Pfizer, use Monogram's technology to develop new antivirals, cancer therapies and vaccines. "The potential oncology pipeline associated with this technology is a natural extension of LabCorp's existing oncology offerings for both clinical trials and commercial clients," a LabCorp release said. Monogram also markets technology that helps doctors optimize their patient treatments.

LabCorp is paying Monogram shareholders $4.55 a share, a big premium on the company's $1.68 close yesterday.

- here's the release
- read the report from Dow Jones

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i